Navigation Links
DecisionView StudyOptimizer 4.3™ Enhances Market-Leading Enrollment Optimization Solution With Greater Visibility Into Site Performance and Cost Forecasting
Date:7/19/2011

SAN FRANCISCO, July 19, 2011 /PRNewswire/ -- DecisionView Inc., a leading provider of software solutions to optimize clinical trial enrollment for life sciences companies, today announced the release of StudyOptimizer 4.3, the latest version of the company's flagship solution for patient enrollment planning, tracking and forecasting.

By providing greater visibility into site performance and cost projections, StudyOptimizer 4.3 significantly improves the ability of global pharmaceutical customers to optimize enrollment plans and deliver clinical trials on time and on budget. And with added support for clustered deployments, enterprise customers get improved performance and reliability, particularly for larger global implementations.

"Drug manufacturers are under increasing market pressure to improve enterprise agility, develop drugs faster, and lower costs," said Alan Louie, Research Director at IDC Health Insights. "The key to enabling effective clinical development transformation is improved operational excellence, in large part driven by better access to and exploitation of organizational data at all levels of the organization. DecisionView is one of the technology vendors delivering on this promise by providing real-time access to clinical enrollment performance data and supporting actionable analytics to reduce risk and increase speed in strategic decision making at all levels of the organization."

StudyOptimizer 4.3 delivers the following compelling new capabilities:

Trial Cost Visibility

The Enrollment & Treatment Cost Analysis capabilities automatically calculate planned, current and projected costs based on assumptions entered for each country participating in a trial. This analysis is presented visually, showing these cost elements over time at specific milestone points (such as Last Patient Screened and Last Patient Randomized), and broken down across regions and countries. Intuitive cost visualization adds significant value by enabling users to quickly assess costs at a glance, which is particularly useful for trials where an over-enrollment strategy is employed.

Site Performance Insights

The StudyOptimizer 4.3 'Sites View' feature has been enhanced to include additional insights on the most recent screening and randomization activity for each site, so trial managers can quickly assess which sites are encountering enrollment problems.

Enhanced scalability and performance

With the StudyOptimizer 4.3 release, customers can now run the application distributed across multiple "cluster nodes" simultaneously, providing improved performance and reliability, particularly for larger implementations.

Global Visibility Into Trial Performance

In StudyOptimizer 4.3, customers have portal-based access to two key charts:


"StudyOptimizer has quickly become a trusted 'source of truth' for our customers because it provides up-to-date information about where trial enrollment is, where it's supposed to be, and where it will end up – all in one place," said Linda Drumright, President and Chief Executive Officer at DecisionView. "StudyOptimizer 4.3 deepens that source of truth by providing visibility into additional key areas.  Now users can evaluate performance on a cost basis as well as time, diagnose site performance more granularly, and share StudyOptimizer information across the enterprise more readily through their enterprise portal strategies."

ABOUT DECISIONVIEW

DecisionView develops innovative web-based software solutions that enable life sciences organizations around the world to improve clinical trial performance. DecisionView's flagship solution, StudyOptimizer, helps organizations optimize clinical trial enrollment by aggregating patient recruitment data from multiple sources and providing analytics, visualizations, and predictive scenario modeling that delivers unique and actionable insight. StudyOptimizer is used by 8 of the top 10 global pharmaceutical companies, and has been used on over 1,250 clinical studies with over 450,000 subjects enrolled in 17 different therapeutic areas across 91 different countries. Investors in the company include Granite Ventures and Aeris Capital. For additional information about DecisionView, go to http://www.decisionview.com or call 415-538-1800.


'/>"/>
SOURCE DecisionView Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DecisionView Launches StudyOptimizer(TM) 4
2. DecisionView to Create Clinical Trial Enrollment Benchmarks
3. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
4. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
5. Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams
6. Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials
7. ClinOps, LLC Enhances Senior Management Team With Addition of Connie Andrews as Senior Vice President of Clinical Operations
8. Infinitus Clinical Research Consolidates- Sino-Indian CRO Enhances Core Capabilities
9. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
10. Hospira Acquires TheraDoc, Enhances Medication Safety and Infection Management Offerings
11. Infinitus Clinical Research Consolidates - Sino-Indian CRO Enhances Core Capabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob ... sciatica in a new episode of "Success Files," which is an award-winning educational ... and investigates each subject in-depth with passion and integrity. , Sciatica occurs when ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
Breaking Medicine News(10 mins):